Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Actavis Inc    

Financials ($)
Sales 2015 18 206 M
EBIT 2015 8 097 M
Net income 2015 505 M
Debt 2015 39 402 M
Yield 2015 -
Sales 2016 17 771 M
EBIT 2016 8 684 M
Net income 2016 924 M
Debt 2016 2 899 M
Yield 2016 -
P/E ratio 2015 -
P/E ratio 2016 110,43
EV / Sales 2015 8,24x
EV / Sales 2016 6,38x
Capitalization 110 544 M
More Financials
Allergan Plc engages in the research, development, and manufacture of pharmaceutical products.The firm offers products under the following brands: BOTOX, Juvederm, Linzess, Namenda, Restasis, Latisse, Teflaro, Lo Loestrin Fe, Bystolic, DORYX, Saphris, Fetzima, Namenda XR, Namzaric, Viberzi,... 
02/22Earnings Release
More about the company
Surperformance© ratings of Actavis Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACTAVIS INC
02/12DJLILLY : U.K. Court Rules in Opponent's Favor on Alimta Patent
02/12DJLILLY : U.K. Court Rules in Opponent's Favor on Alimta Patent
02/12 Eli Lilly loses latest round in UK drug patent battle
02/11DJTeva Pharmaceuticals Reports Sales Decline
02/11DJTeva Pharmaceuticals Reports Sales Decline
02/08DJPfizer Files 8K - Changes Executive Management
02/08DJPfizer Outlines Post-Merger Management Slate
02/08DJPfizer Outlines Post-Allergan Merger Management Slate
More news
Sector news : Pharmaceuticals - NEC
03:36p TEVA PHARMACEUTICAL : BRIEF: Teva CEO Vigodman's 2015 salary cost: $5.7m
02/13 NOVO NORDISK A/S : Proposed changes in composition of the Board of Directors of ..
02/12 AMGEN : Mystery cannabis 'consortium' reportedly interested in Longmont's Amgen ..
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions